 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...3940414243444546474849...100101» |
- || letrozole / Generic mfg.
Clinical, Journal: Clinical efficacy of letrozole and clomiphene in the treatment of infertility due to polycystic ovary syndrome. (Pubmed Central) - Dec 6, 2021
No abstract available
- Piqray (alpelisib) / Novartis
THE ALPELISIB (ALP) EXPERIENCE IN THE SOLAR-1 AND BYLIEVE STUDIES: PERSPECTIVES FOR PRACTITIONERS CARING FOR PATIENTS (PTS) WITH HORMONE RECEPTOR-POSITIVE (HR+), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2–) ADVANCED BREAST CANCER (ABC) ([VIRTUAL]) - Dec 2, 2021 - Abstract #ABC62021ABC6_4;
P2, P3
Pts with HR+, HER2– ABC are often treated with endocrine therapy (ET; fulvestrant [FUL], or aromatase inhibitor [AI]) ± cyclin-dependent kinase 4/6 inhibitor (CDK4/6i)...In Cohorts A and B (primary endpoint reported), adding ALP to FUL or letrozole, respectively, was effective in pts treated with CDK4/6is + AI or FUL as immediate prior tx; 50.4% and 46.1% of pts were alive and without progression at 6 mo...AEs were manageable with close monitoring and early intervention. Thus, ALP should be considered for tx of pts with HR+, HER2–, PIK3CA-mut ABC.
- | letrozole / Generic mfg.
Preclinical, Journal: Beneficial phytoestrogenic effects of resveratrol on polycystic ovary syndromein rat model. (Pubmed Central) - Dec 2, 2021
Thus, ALP should be considered for tx of pts with HR+, HER2–, PIK3CA-mut ABC. Together things findings suggest that resveratrol may represent an effective tool for treating PCOS owing to its phytoestrogenic properties.
- | letrozole / Generic mfg.
Retrospective data, Journal: Stimulated cycle versus artificial cycle for frozen embryo transfer in patients with polycystic ovary syndrome: a Meta-analysis. (Pubmed Central) - Dec 2, 2021
PCOS patients using the mild ovarian stimulation cycle for endometrial preparation undergoing FET had similar LBR, OPR, CPR and IR compared with the AC. The letrozole-stimulated protocol may be a reasonable choice for endometrial preparation before FET for women with PCOS.
- | Soltamox (tamoxifen citrate) / Jazz
Trial completion date, Trial primary completion date: The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer (clinicaltrials.gov) - Dec 1, 2021
P2, N=30, Recruiting, Sponsor: Johns Hopkins University
The letrozole-stimulated protocol may be a reasonable choice for endometrial preparation before FET for women with PCOS. Trial completion date: Nov 2021 --> Nov 2022 | Trial primary completion date: Nov 2021 --> Nov 2022
- | Reolysin (pelareorep) / Oncolytics, Andrus Reo
Trial completion date, Trial primary completion date: AWARE-1: A Window-of-opportunity Study of Pelareorep in Early Breast Cancer (clinicaltrials.gov) - Dec 1, 2021
P1, N=29, Recruiting, Sponsor: Oncolytics Biotech
Trial completion date: Nov 2021 --> Nov 2022 | Trial primary completion date: Nov 2021 --> Nov 2022 Trial completion date: Dec 2020 --> May 2022 | Trial primary completion date: Oct 2020 --> Feb 2022
- ||| Ibrance (palbociclib) / Pfizer, letrozole / Generic mfg.
Fulvestrant–Palbociclib vs Letrozole–Palbociclib as Initial Therapy for Endocrine-Sensitive, HR-Positive, ERBB2-Negative Advanced #BreastCancer Expert comment by Reshma L. Mahtani DO - @DrReshmaMahtani #bcsm https://t.co/nbjbyF2Mer (Twitter) - Nov 30, 2021
- | Mifeprex (mifepristone) / Danco Laboratories
Preclinical, Journal: Effect of GnRH-antagonist, mifepristone and letrozole on preventing ovarian hyperstimulation syndrome in rat model. (Pubmed Central) - Nov 29, 2021
GnRH-ant, mifepristone and letrozole are beneficial in preventing the progression of OHSS through different luteolytic mechanisms. Cocktail style treatment shows enhanced synergistic effect on preventing the progression of OHSS.
- | letrozole / Generic mfg.
Preclinical, Journal: Case study in 21 century ecotoxicology: using in vitro aromatase inhibition data to predict short term in vivo responses in adult female fish. (Pubmed Central) - Nov 29, 2021
Female fathead minnows were then exposed to 3 of those chemicals: letrozole, epoxiconazole, and imazalil in concentration-response (5 concentrations plus control) for 24 h...However, the inclusion of measured plasma concentrations of the test chemicals as inputs improved model predictions, with all predictions falling within the range of measured values. Results highlight both the utility and limitations of the qAOP and its potential use in 21 century ecotoxicology.
- | letrozole / Generic mfg.
Journal: Nanoemulsion and Solid Nanoemulsion for Improving Oral Delivery of a Breast Cancer Drug: Formulation, Evaluation, and a Comparison Study. (Pubmed Central) - Nov 29, 2021
Letrozole (LZ) is an aromatase inhibitor, which inhibits the formation of estrogens from androgens...FT-IR showed no significant variations in position and shape of the absorption peaks between the pure drug and optimal formulation diagrams. This novel nanoemulsion technology aids in improving the solubility of poorly water-soluble drugs, particularly the SNE delivery method, which has a higher in-vitro release rate and expiration date of LZ than others.
- | Ibrance (palbociclib) / Pfizer
Journal, HEOR: Handling Uncertainty in Cost-Effectiveness Analysis: Budget Impact and Risk Aversion. (Pubmed Central) - Nov 29, 2021
Moreover, we show that the cost-effectiveness risk-aversion curve (CERAC) allows the analyst to incorporate different levels of risk-aversion into the analysis and can, therefore, be used to inform decision-makers who are risk-averse. We use data from a published cost-effectiveness model of palbociclib in addition to letrozole versus letrozole alone for the treatment of oestrogen-receptor positive, HER-2 negative, advanced breast cancer to demonstrate the differences between CEAC, CEAFC and CERAC, and show how these can jointly be used to inform decision and policy makers.
- letrozole / Generic mfg.
UPDATE ON FERTILITY PRESERVATION () - Nov 27, 2021 - Abstract #EHOC2021EHOC_395;
For estrogen sensitive tumors including breast and endometrial cancers, safer ovarian stimulation protocols incorporating letrozole were defined with high success rates...However, with increased clinical success together with increasing number of healthy live births in recent years, ovarian tissue freezing is now considered as an "acceptable" method for fertility preservation. The feasibility of autologous hematopoietic stem cell transplantation to improve pregnancy rates in patients with poor ovarian reserve has also been investigated with reported success rates in limited number of recent studies.
- | Mifeprex (mifepristone) / Danco Laboratories
Preclinical, Journal: Ascorbic Acid and Alpha-Tocopherol Contribute to the Therapy of Polycystic Ovarian Syndrome in Mouse Models. (Pubmed Central) - Nov 25, 2021
AA and ATE also decreased ovarian weight and mostly resolved cysts in the ovaries and congestion in the uterus. This study has shown that AA and ATE are beneficial in the therapy of PCOS.
- || Ibrance (palbociclib) / Pfizer, Herceptin (trastuzumab) / Roche
P2 data, Journal: Palbociclib and trastuzumab in HER2-positive advanced breast cancer: Results from the phase II SOLTI-1303 PATRICIA trial. (Pubmed Central) - Nov 24, 2021
Palbociclib in combination with trastuzumab is safe and exhibits promising survival outcomes in trastuzumab pre-treated ER-positive/HER2-positive advanced breast cancer with a PAM50 luminal A or B subtype. The enrollment was stopped prematurely and a new randomized cohort was opened in this population.
- | letrozole / Generic mfg.
Trial completion date: RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF (clinicaltrials.gov) - Nov 23, 2021
P4, N=41, Active, not recruiting, Sponsor: Weill Medical College of Cornell University
The enrollment was stopped prematurely and a new randomized cohort was opened in this population. Trial completion date: Sep 2021 --> Sep 2022
- | Herceptin (trastuzumab) / Roche, trastuzumab/pertuzumab (EG13084) / EirGenix, Perjeta (pertuzumab) / Roche
New trial: Neoadjuvant Treatment of Breast Cancer (clinicaltrials.gov) - Nov 22, 2021
P=N/A, N=300, Not yet recruiting, Sponsor: National Institute of Oncology, Hungary
- || Review, Journal: The role of ERα36 in cell type-specific functions of estrogen and cancer development. (Pubmed Central) - Nov 21, 2021
These factors influence the ERK kinetic and determine the ultimate mitogenic or antimitogenic signaling of estrogen, leading to cell survival or cell death. In this review, we summarize the recent organ-specific, cellular and molecular events and the mechanisms involved in estrogen effects mediated through the ERα36/ ERα66 with a particular focus on carcinomas where more clinical information has recently emerged.
- || Ibrance (palbociclib) / Pfizer, letrozole / Generic mfg., Keytruda (pembrolizumab) / Merck (MSD)
Clinical, P1/2 data, Journal, PD(L)-1 Biomarker: Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer. (Pubmed Central) - Nov 21, 2021
The combination of palbociclib, pembrolizumab and letrozole is well tolerated, and a complete response rate of 31% was identified in HR MBC patients who received this combination as front-line therapy. Confirmatory trials are required to better understand the immune-priming effects of CDK4/6 inhibitors.
- ||| everolimus / Generic mfg.
Clinical, P3 data, Journal: Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial. (Pubmed Central) - Nov 21, 2021
P3
EVE + AIs did not significantly impact on the outcome of metastatic breast cancer patients deemed suitable for first-line chemotherapy. Also taking into account treatment tolerability, maintenance endocrine therapy remains the standard.
- Ibrance (palbociclib) / Pfizer
On-treatment derived neutrophil-to-lymphocyte ratio and response to palbociclib and letrozole: Analysis of a multicenter retrospective cohort and the PALOMA-2 study with immune correlates (Room D [VIRTUAL]) - Nov 20, 2021 - Abstract #KSMO2021KSMO_66;
- || letrozole / Generic mfg.
Trial completion date, Trial primary completion date: Evaluation of IM Letrozole ISM (clinicaltrials.gov) - Nov 18, 2021
P1, N=120, Active, not recruiting, Sponsor: Rovi Pharmaceuticals Laboratories
Also taking into account treatment tolerability, maintenance endocrine therapy remains the standard. Trial completion date: Oct 2021 --> Jan 2022 | Trial primary completion date: Oct 2021 --> Jan 2022
- Ibrance (palbociclib) / Pfizer
Predictors of progression-free survival in patients with metastatic breast cancer receiving palbociclib with letrozole ([VIRTUAL]) - Nov 16, 2021 - Abstract #NCRI2021NCRI_199;
PS≥1, liver metastases or any visceral metastases were associated with a significantly shorter PFS. Impact statement This study suggests PS and metastatic pattern are important predictors of PFS and could be used to influence monitoring decisions in patients with MBC.
- | letrozole / Generic mfg., everolimus / Generic mfg., exemestane / Generic mfg.
Preclinical, Journal: Chemical inhibitor anticancer drugs regulate mechanical properties and cytoskeletal structure of non-invasive and invasive breast cancer cell lines: Study of effects of Letrozole, Exemestane, and Everolimus. (Pubmed Central) - Nov 16, 2021
While metabolic activity of cell lines was highly affected by drug treatment, significant alterations in Young's modulus of cell bodies, nuclear areas, and actin content and distribution were reported with higher impact on invasive cells. It was concluded that regulation of mechanical behavior of cells by all three drugs emphasizes the cross talk between chemical and physical signaling cascades, and describes a correlation between biological and physical behaviors of cancer cells which might give an insight to a better understanding of mechanisms by which anti-cancer drugs function to enhance their performances.
- | letrozole / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Protocols of IVF/ICSI in Poor Responders (clinicaltrials.gov) - Nov 16, 2021
P3, N=132, Completed, Sponsor: Cairo University
It was concluded that regulation of mechanical behavior of cells by all three drugs emphasizes the cross talk between chemical and physical signaling cascades, and describes a correlation between biological and physical behaviors of cancer cells which might give an insight to a better understanding of mechanisms by which anti-cancer drugs function to enhance their performances. Recruiting --> Completed | Trial completion date: Mar 2022 --> Oct 2021 | Trial primary completion date: Jun 2021 --> Sep 2021
- | Enrollment open: De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) (clinicaltrials.gov) - Nov 15, 2021
P3, N=1670, Recruiting, Sponsor: NRG Oncology
Recruiting --> Completed | Trial completion date: Mar 2022 --> Oct 2021 | Trial primary completion date: Jun 2021 --> Sep 2021 Not yet recruiting --> Recruiting
- || Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
Clinical, Journal: Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2- Advanced Breast Cancer. (Pubmed Central) - Nov 12, 2021
Using MAIC to adjust for trial differences, OS comparisons favored RIB+FUL over PAL+LET as first-line treatment in postmenopausal patients with HR+/HER2- ABC. These exploratory results suggest a significant increase in OS benefit with RIB treatment compared with PAL.
- | leuprorelin depot / Generic mfg., dydrogesterone / Generic mfg.
Retrospective data, Journal: Dydrogesterone in the treatment of endometriosis: evidence mapping and meta-analysis. (Pubmed Central) - Nov 12, 2021
Limited evidence suggests that dydrogesterone may have some advantages over gestrinone, GnRH agonists, and other therapeutic interventions in treating endometriosis. However, this conclusion should be interpreted with caution.
- | letrozole / Generic mfg.
Preclinical, Journal: Ameliorative effects of fisetin in letrozole-induced rat model of polycystic ovary syndrome. (Pubmed Central) - Nov 12, 2021
However, this conclusion should be interpreted with caution. Our results showed that, fisetin treatment caused significant alleviating effects by restoring PCOS-induced alterations in the key genes involved in energy homeostasis and antioxidant enzymes, suggesting that it may have a key role in combating with PCOS.
- || Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date, IO biomarker, MSi-H Companion diagnostic, PARP Companion diagnostic, PD(L)-1 companion diagnostic: AFT-50 EndoMAP: A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer (clinicaltrials.gov) - Nov 11, 2021
P1/2, N=60, Recruiting, Sponsor: Alliance Foundation Trials, LLC.
Our results showed that, fisetin treatment caused significant alleviating effects by restoring PCOS-induced alterations in the key genes involved in energy homeostasis and antioxidant enzymes, suggesting that it may have a key role in combating with PCOS. Trial completion date: Sep 2025 --> Oct 2026 | Trial primary completion date: Sep 2024 --> Oct 2025
- | letrozole / Generic mfg.
Journal: Live birth rate of twin pregnancies after frozen embryo transfer: natural cycle versus ovulation induction regimens. (Pubmed Central) - Nov 11, 2021
Trial completion date: Sep 2025 --> Oct 2026 | Trial primary completion date: Sep 2024 --> Oct 2025 The live birth rate in twin pregnancies after FET is comparable between mNC or OI regimens for endometrium preparation.
- | fulvestrant / Generic mfg.
Trial completion date, Trial primary completion date: Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study (clinicaltrials.gov) - Nov 11, 2021
P2, N=124, Recruiting, Sponsor: M.D. Anderson Cancer Center
The live birth rate in twin pregnancies after FET is comparable between mNC or OI regimens for endometrium preparation. Trial completion date: Apr 2021 --> Apr 2022 | Trial primary completion date: Apr 2021 --> Apr 2022
- || Ibrance (palbociclib) / Pfizer
Clinical, Journal, Combination therapy, BRCA Biomarker: Which Clinicopathologic Parameters Suggest Primary Resistance to Palbociclib in Combination With Letrozole as the First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer? (Pubmed Central) - Nov 10, 2021
Our prediction model might be helpful for considering the first-line treatment strategies. Further well-designed clinical trials would be warranted to validate our prediction model.
- | letrozole / Generic mfg.
Enrollment open: Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI) (clinicaltrials.gov) - Nov 9, 2021
P2, N=28, Recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
Further well-designed clinical trials would be warranted to validate our prediction model. Not yet recruiting --> Recruiting
- || tamoxifen / Generic mfg.
Clinical, Clinical data, Review, Journal: Impact of obesity on clinical outcomes in hormone receptor-positive breast cancer: a systematic review. (Pubmed Central) - Nov 7, 2021
The results of our systematic review highlight a need for further research exploring the optimal endocrine therapies for obese women. There is insufficient evidence at present to recommend tailoring adjuvant endocrine therapy with use of specific AIs or for dosing modifications of AIs in this patient population.
- | minocycline / Generic mfg.
Preclinical, Journal: Beneficial effects of minocycline on the ovary of polycystic ovary syndrome mouse model: Molecular docking analysis and evaluation of TNF-α, TNFR2, TLR-4 gene expression. (Pubmed Central) - Nov 7, 2021
After 28 days, the mice were divided into five groups, including control, PCOS, minocycline control, minocycline PCOS model (50 mg/kg), and letrozole PCOS (0.5 mg/kg)...Minocycline treatment in PCOS led to a significant decrease in E2 (P < 0.01) and graafian follicles (P < 0.001) and a significant increase in the CL numbers (P < 0.05). Our findings showed the positive effects of minocycline on estradiol level, CL and graafian follicles counts, suggesting that minocycline might inhibit these proteins and improve ovulation in our mouse model of PCOS.
- || letrozole / Generic mfg.
PK/PD data, Journal: The pharmacokinetics of letrozole and its effect on gonadotropins in anestrous ewes. (Pubmed Central) - Nov 6, 2021
This increase in FSH concentration may create a potential for the use of letrozole in ovarian superstimulation protocols. Favorable pharmacokinetic properties (long t and good bioavailability) of letrozole for IM and SC routes require further investigation before use in estrus induction or estrus synchronization protocols in sheep.
- || letrozole / Generic mfg., clomifene citrate / Generic mfg.
Clinical, Journal: Comparison of the efficacy of letrozole stair-step protocol with clomiphene citrate stair-step protocol in the management of clomiphene citrate-resistant polycystic ovary syndrome patients. (Pubmed Central) - Nov 5, 2021
The LTZ stair-step protocol revealed higher ovulation, clinical pregnancy, and live birth rates with a shorter time to achieve ovulation than the CC stair-step protocol. Increment of the dose in the same cycle in both protocols did not cause any additional severe side effects.
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Metastases: Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Nov 4, 2021
P2, N=30, Active, not recruiting, Sponsor: City of Hope Medical Center
Increment of the dose in the same cycle in both protocols did not cause any additional severe side effects. Trial completion date: Oct 2021 --> Dec 2022
- || Ibrance (palbociclib) / Pfizer
Clinical data, Journal, Real-world evidence: Real-World Clinical Data of Palbociclib in Asian Metastatic Breast Cancer Patients: Experiences from Eight Institutions. (Pubmed Central) - Nov 4, 2021
To our knowledge, this is the first real-world data of palbociclib reported in Asia. Palbociclib showed comparable benefit to previous phase 3 trials in Asian patients during daily clinical practice.
- | Piqray (alpelisib) / Novartis
Preclinical, Journal: Effects of PI3K inhibition in AI-resistant breast cancer cell lines: autophagy, apoptosis, and cell cycle progression. (Pubmed Central) - Nov 4, 2021
Palbociclib showed comparable benefit to previous phase 3 trials in Asian patients during daily clinical practice. These results corroborate the lack of cross-resistance between AIs verified in the clinic, excluding autophagy as a mechanism of resistance to Ana or Let and supporting the ongoing clinical trials combining BYL-719 with AIs.
- ||| letrozole / Generic mfg., tamoxifen / Generic mfg.
Clinical, P3 data, Journal: Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. (Pubmed Central) - Nov 4, 2021
P3
In postmenopausal patients with breast cancer who received 2-3 years of tamoxifen, extended treatment with 5 years of letrozole resulted in a significant improvement in disease-free survival compared with the standard 2-3 years of letrozole. Sequential endocrine therapy with tamoxifen for 2-3 years followed by letrozole for 5 years should be considered as one of the optimal standard endocrine treatments for postmenopausal patients with hormone receptor-positive breast cancer.
- || letrozole / Generic mfg., exemestane / Generic mfg.
Clinical, Journal: Lack of cross-resistance between non-steroidal and steroidal aromatase inhibitors in breast cancer patients: the potential role of the adipokine leptin. (Pubmed Central) - Nov 4, 2021
Our findings suggest an additional and direct effect of exemestane on CYP-19 (aromatase) synthesis presumably due to effects on the CYP19 promoter use that is not present during therapy with the non-steroidal aromatase inhibitor letrozole. Our findings provide new insights into the influence of clinically important aromatase inhibitors on cytokine levels in vivo that contribute to the understanding of the clinically observed lack of cross-resistance between non-steroidal and steroidal aromatase inhibitors in breast cancer patients.
- | letrozole / Generic mfg., clomifene citrate / Generic mfg.
New trial: Vitamin D Supplementation and Improvement of PCOS Therapy and IVF Outcomes in Infertile Saudi Women (clinicaltrials.gov) - Nov 4, 2021
P=N/A, N=700, Not yet recruiting, Sponsor: Umm Al-Qura University
- || Ibrance (palbociclib) / Pfizer
Clinical, Clinical data, Observational data, Journal: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. (Pubmed Central) - Oct 31, 2021
The present study demonstrates that concomitant use of PPIs in mBC patients treated with palbociclib has a detrimental effect on PFS. Therefore, it is recommended to prescribe PPIs with caution in these patients, strictly adhering to the indications in the summary of product characteristics (RCP).
- || Kisqali (ribociclib) / Novartis
Clinical, Journal: Serial single-cell genomics reveals convergent subclonal evolution of resistance as early-stage breast cancer patients progress on endocrine plus CDK4/6 therapy. (Pubmed Central) - Oct 31, 2021
P2
In contrast, cancer cells maintaining estrogen signaling during mono- or combination therapy showed potentiation of CDK4/6 activation and ERK upregulation through ERBB4 signaling. These results indicate that combination therapy in early-stage ER+ breast cancer leads to emergence of resistance through a shift from estrogen to alternative growth signal-mediated proliferation.
- | letrozole / Generic mfg.
Journal: Could human chorionic gonadotropin modulate interleukin 1β to be a successful pregnancy predictor or not? (Pubmed Central) - Oct 30, 2021
HCG did increase the mean level of interleukin 1β, but it was not significant. High interleukin 1β level is a significant predictor of successful pregnancy in IVF cycles.
- ||| letrozole / Generic mfg.
Clinical, P3 data, Journal: Continuous vs intermittent extended adjuvant letrozole for breast cancer: Final results of randomized phase 3 SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy. (Pubmed Central) - Oct 30, 2021
Extended adjuvant endocrine therapy by intermittent administration of letrozole did not improve disease-free survival compared to continuous use despite the recovery of circulating estrogen level. The similar disease-free survival coupled with previously reported quality-of-life advantages suggest intermittent extended treatment is a valid option for patients who require or prefer a treatment interruption.
- || letrozole / Generic mfg.
Clinical, Journal: Off-label use of Letrozole in Chinese Short Pubertal Boys: Effectiveness, Safety, and Exposure-Response Analysis. (Pubmed Central) - Oct 29, 2021
The similar disease-free survival coupled with previously reported quality-of-life advantages suggest intermittent extended treatment is a valid option for patients who require or prefer a treatment interruption. Letrozole treatment in Chinese pubertal populations should be further optimized, and more personalized therapies should be developed.
- || letrozole / Generic mfg.
Review, Journal: Fertility Issues in Polycystic Ovarian Disease: A Systematic Approach. (Pubmed Central) - Oct 27, 2021
Ovulation induction is considered first-line management of infertility in women with PCOS, with letrozole superior to clomiphene. Women with PCOS undergoing in vitro fertilization are high risk for ovarian hyperstimulation syndrome but also have a higher live birth rate compared with controls.
- || ipatasertib (RG7440) / Roche
Trial completion date, Trial primary completion date, Metastases: AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC) (clinicaltrials.gov) - Oct 27, 2021
P1, N=60, Recruiting, Sponsor: Massachusetts General Hospital
Women with PCOS undergoing in vitro fertilization are high risk for ovarian hyperstimulation syndrome but also have a higher live birth rate compared with controls. Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2022 --> Dec 2022